The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Parolia, Abhijit ^a,b,c   Crea, Francesco ^a,b,c   Xue, Hui ^b,c   Wang, Yuwei ^b,c   Mo, Fan ^c   Ramnarine, Rohan ^c   Liu, Hsuan ^b   Lin, Dong ^a,b,c   Saidy, Nur ^a,b   Clermont, Pier Luc ^a,b   Cheng, Hongwei ^b,c   Collins, Colin ^c   Wang, Yuzhuo ^b,c   Helgason, Cheryl D ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Androgen receptor; AR regulation; lncRNAs; Long non coding RNAs; PCAT18; PCGEM1; PRNCR1; Prostate cancer; Sub cellular localization

Indexed keywords

ANDROGEN RECEPTOR; LONG UNTRANSLATED RNA; PROSTATE CANCER ASSOCIATED NON CODING RNA 1; PROSTATE CANCER GENE EXPRESSION MARKER 1; UNCLASSIFIED DRUG; ANDROGEN; AR PROTEIN, HUMAN; PCGEM1 NON-CODING RNA, HUMAN;

ARTICLE; CANCER PATIENT; CASTRATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY RNA SEQUENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84924264072     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0314-4     Document Type: Article

References (29)

1. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354-61.
2. Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? Trends Mol Med. 2014;20(8):428-36.
3. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775-89.
4. Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 2013;33:1-16.
5. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1(5):391-407.
6. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29(8):742-9.
7. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45:1392-8.
8. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly over expressed in prostate cancer. Cancer Res. 1999;59(23):5975-9.
9. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 2000;97(22):12216-21.
10. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011;102(1):245-52.
11. Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, et al. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia. 2014;16(12):1121-7.
12. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010;58:475-81.
13. Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 2014;5(3):764-74.
14. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006;25(3):135-41.
15. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004;23(2):605-11.
16. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013;500(7464):598-602.
17. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, et al. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014;5(6):1434-8.
18. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
19. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-44.
20. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 2014;14(3):187-98.
21. Fry CJ, Farnham PJ. Context-dependent transcriptional regulation. J Biol Chem. 1999;274(42):29583-6.
22. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013;23(1):35-47.
23. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014;74(4):1272-83.
24. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002;3(7):RESEARCH0032.
25. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 2013;333(2):213-21.
26. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA. 2007;13(3):313-6.
27. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010;31(3):350-8.
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
29. Xue Y, Wang M, Kang M, Wang Q, Wu B, Chu H, et al. Association between lncrna PCGEM1 polymorphisms and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):139-44.